Loading…
Chinese pharmaceutical company making traditional-Chinese-medicine-derived drugs, notably for kidney disease.
Chinese pharmaceutical company making traditional-Chinese-medicine-derived drugs, notably for kidney disease.
In one line: A niche Chinese TCM-derived nephrology drug maker.
Moat: narrow (brand, IP / patents). Branded, patent-protected TCM formulations in a niche nephrology segment.
Headquarters: Guangzhou, China · Founded: 1998 · Employees: 3,115
Size Consun Pharmaceutical (1681.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $1.65B, the 466th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$15.78 on 6 Nov 2026.
Performance Over six months the shares gained 4.7%, against -4.2% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue grew 15.1% over the last twelve months (peer median +11.4%); the operating margin is 35.5% (peer median 11.5%).
Valuation It trades at 9.2× forward earnings against a peer median of 27.9× (cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -29 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 60.0 points above its cost of capital (7.2% WACC).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$4.06B | HK$3.71B | HK$3.22B | HK$2.86B | HK$2.72B |
| Revenue growth | — | +15% | +12% | +5% | — |
| Gross profit | HK$3.25B | HK$2.89B | HK$2.43B | HK$2.12B | HK$2.05B |
| EBITDA | HK$1.52B | HK$1.32B | HK$1.11B | HK$933M | HK$903M |
| Net income | HK$1.31B | HK$1.17B | HK$987M | HK$867M | HK$794M |
| Free cash flow | HK$1.73B | HK$1.34B | HK$1.10B | HK$898M | HK$1.08B |
| Capital expenditure | HK$81.1M | HK$74.3M | HK$118M | HK$58.1M | HK$60.0M |
| Total debt | n/a | HK$299M | HK$284M | HK$563M | HK$517M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Consun Pharmaceutical 1681.HK | $1.65B | +5% | +15% | 35% | 9.2× | -15.1% |
| China Resources Pharmaceutical 3320.HK | $3.74B | -11% | +8% | 4% | 6.0× | -5.3% |
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | $4.56B | -23% | +6% | 3% | 7.3× | 0.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1681.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.3% | -0.7% | 6th highest of 21 |
| 6-month return | +4.7% | -4.2% | 8th highest of 20 |
| Distance from 52-week high | -19.0% | -22.9% | 10th highest of 21 |
| Revenue growth (TTM) | +15.1% | +11.4% | 10th highest of 19 |
| Operating margin | 35.5% | 11.5% | highest of 19 |
| Forward P/E | 9.2× | 27.9× | cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -15.1% | 10.7% | least demanding of 13 |
| Growth delivered (Del g) | +13.5% | +8.3% | 6th highest of 13 |
| Hurdle (Req g minus delivered) | -28.6 pp | -2.1 pp | 2nd least demanding of 13 |
| ROIC minus cost of capital | +60.0 pp | +1.4 pp | highest of 20 |
| EV / EBITDA | 5.9× | 32.3× | cheapest of 9 |
| Net debt / EBITDA | -2.9× | -0.4× | least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +5% | +15% | 35% | 9.2× | -15.1% | +13.5% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.67B | -14% | -13% | 6% | 13.2× | -6.0% | -5.6% |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.67B | +1% | -4% | 15% | 47.5× | 6.7% | -4.3% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| NATCO Pharma NATCOPHARM.NS | India | $1.68B | -30% | -21% | 25% | 18.8× | 15.3% | +19.0% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.69B | -25% | +31% | 10% | n/a | 49.3% | +23.0% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.62B | -4% | +7% | 17% | 16.2× | -4.5% | +6.8% |
| Eton Pharmaceuticals ETON | United States | $1.61B | +236% | +81% | 16% | 27.9× | 39.6% | +359.6% |
| SELLAS Life Sciences SLS | United States | $1.70B | +68% | n/a | n/a | n/a | n/a | n/a |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.60B | -5% | +16% | 24% | n/a | -4.1% | +0.2% |
| Faes Farma FAE.MC | Spain | $1.71B | +5% | +32% | 14% | 17.1× | 3.1% | +9.9% |
| Yifan Pharmaceutical 002019.SZ | China | $1.72B | -14% | -5% | 8% | 27.8× | n/a | n/a |
| LigaChem Biosciences 141080.KS | South Korea | $1.59B | -68% | -33% | -208% | n/a | n/a | n/a |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.58B | -4% | +16% | 9% | 29.0× | n/a | n/a |
| Xiamen Kingdomway 002626.SZ | China | $1.58B | +15% | -3% | 11% | 30.0× | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.58B | +40% | +17% | 18% | 63.7× | 37.6% | +16.6% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.56B | -5% | +4% | 9% | 18.5× | -5.8% | +1.9% |
| Cohance Lifesciences COHANCE.NS | India | $1.75B | -11% | +41% | 6% | 82.6× | n/a | n/a |
| Agios Pharmaceuticals AGIO | United States | $1.76B | +6% | +141% | -467% | n/a | n/a | n/a |
| Indegene INDGN.NS | India | $1.56B | +15% | +36% | 12% | 27.5× | 29.6% | +29.4% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.76B | -25% | -13% | 12% | 63.3× | 14.7% | -14.0% |